Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Validation of the IPF-specific version of St. George's Respiratory Questionnaire

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Risk factors for diagnostic delay in idiopathic pulmonary fibrosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Prevalence and course of disease after lung resection in primary ciliary dyskinesia: a cohort & nested case-control study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Electronic applications for the CFQ-R scoring

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Fibrogenesis and inflammation contribute to the pathogenesis of cirrhotic cardiomyopathy

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Validation of suPAR turbidimetric assay on Cobas® (c502 and c702) and comparison to suPAR ELISA

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Elevated suPAR Is an Independent Risk Marker for Incident Kidney Disease in Acute Medical Patients

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: The inflammatory biomarker soluble urokinase plasminogen activator receptor (suPAR) is elevated in severe acute and chronic medical conditions and has been associated with short-term mortality. The role of suPAR in predicting risk of death following an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) has never been studied. We hypothesized that increased suPAR is an independent predictor of short-term mortality in patients admitted to hospital with COPD or acute respiratory failure.

METHODS: This retrospective cohort study from a university hospital in the Capital Region of Denmark included 2838 acutely admitted medical patients with COPD as primary (AECOPD) or secondary diagnosis, who had plasma suPAR measured at the time of admission between November 18th, 2013 to September 30th, 2015 and followed until December 31st, 2015. Primary outcomes were 30- and 90-days all-cause mortality. Association of suPAR and mortality was investigated by Cox regression analyses adjusted for age, sex, CRP values and Charlson comorbidity index.

RESULTS: For patients with AECOPD or underlying COPD, median suPAR levels were significantly higher among patients who died within 30 days compared with those who survived (5.7 ng/ml (IQR 3.8-8.1) vs. 3.6 ng/ml (2.7-5.1), P < 0.0001). Increasing suPAR levels independently predicted 30-day mortality in patients with COPD with a hazard ratio of 2.0 (95% CI 1.7-2.4) but not respiratory failure.

CONCLUSIONS: In this large group of acutely admitted patients with COPD, elevated suPAR levels were associated with increased risk of mortality. The study supports the value of suPAR as a marker of poor prognosis.

Original languageEnglish
JournalRespiratory Research
Volume19
Issue number97
ISSN1465-9921
DOIs
Publication statusPublished - 1 May 2018

ID: 54350477